ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, revealing a transformative year characterized by substantial balance sheet growth and strategic long-term asset positioning. Total assets surged to $21,062,203, a 179% year-over-year increase from $7,539,907 in 2024.
Net property and equipment rose significantly to $12,835,409, up from $511,088 in the prior year, primarily driven by the strategic acquisition of land and development-oriented land assets in Asia. The title transition to ABVC and its subsidiary is in process. As of December 31, 2025, the company reported total assets of $21.06 million, property and equipment (net) of $12.84 million, operating lease right-of-use assets of $1.91 million, and long-term investments of $1.88 million.
Management believes the 2025 fiscal year represents a structural strengthening of the company’s balance sheet and asset foundation. Over prior years, ABVC strategically licensed its core drug programs to a subsidiary and related parties: its CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this structure, subsidiary and related parties handle advancing clinical development, ABVC reduces direct clinical cash burn exposure, and ABVC retains licensing economics and equity participation. This model has enabled ABVC to separate development risk from long-term value participation while preserving upside and mitigating capital intensity.
In parallel with its licensing framework, ABVC is strengthening its long-term infrastructure positioning in Asia through direct or subsidiary strategic land asset acquisitions. The Longtan District, Taoyuan property, comprising 5,995.41 square meters, was valued at $4.6 million as of December 31, 2025. The land is being held as a strategic reserve asset with flexible future use potential, including healthcare-related applications, demonstration facilities, or supportive infrastructure aligned with biotechnology and long-term care initiatives. The company has adopted a disciplined “land-first, development-later” approach, preserving strategic optionality while strengthening tangible asset backing.
The Puli Township, Nantou property, spanning 69,230.90 square meters, was independently appraised as of January 30, 2026, at approximately USD $8.0 million. The Puli development plan is designed as a staged, long-term initiative focused on establishing a medicinal plant cultivation base, supporting pharmaceutical supply chain localization, creating an agricultural-biotech integration platform, and developing value-added processing and storage infrastructure. Projected annual cultivation and processing output value is estimated between approximately $60,000 to $360,000, depending on processing depth and value enhancement. The Puli site represents a scalable long-term development platform with phased investment over multiple years.
The potential for a substantial increase in fixed and real assets reflects ABVC’s strategic evolution toward a hybrid model combining intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible long-term physical assets. ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. The company utilizes in-licensed technology from its network of research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
